Purpose: To independently apply an analytical model for equivalent dose from neutrons produced in a passive-scattering proton therapy treatment unit, H.
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Introduction
Nontherapeutic stray neutrons are produced in the delivery of proton therapy beams. These neutrons are of concern because of their high and uncertain relative biological effectiveness for late effects such as carcinogenesis (Grahn et al 1992 , Wolf et al 2000 , Hollander et al 2003 , Kuhne et al 2009 . Neutrons produced in the patient are unavoidable, but neutrons generated in the treatment unit, i.e., "external neutrons," may be attenuated by simple modifications to the treatment unit (Taddei et al 2008 , Taddei et al 2009b , Brenner et al 2009 . In passive-scattering proton therapy (PSPT), the final collimating aperture is the chief source of patient exposures to external neutrons (Pérez-Andújar et al 2009 , Matsumoto et al 2016 . Because commercial treatment planning systems in proton therapy do not calculate the equivalent dose from external neutrons, H, a vast number of research studies into H have applied detailed Monte Carlo ( . For brevity, we shall refer to this model as the LSU-MDA model. The model estimates H per prescribed proton absorbed dose, DRx, in a water phantom. The version reported by Schneider et al (2015) was simpler to configure and use than previous versions and offered continuous applicability from 100 to 250 MeV in proton beam energy. Eley et al (2015) integrated the model into a proton therapy treatment planning system and extended the model to include range modulation and arbitrary collimator shapes. However, all of these studies were performed by the team who developed the LSU-MDA model, and, to date, an independent application had not been performed in a clinically relevant case.
The purpose of this study was to independently apply and evaluate the LSU-MDA model for H in PSPT in clinically realistic circumstances. Using the model, we estimated the average H in organs and tissues, T, at risk for subsequent malignant neoplasms (SMNs), HT, for two children who received PSPT to an intracranial target. To do so, we adjusted the LSU-MDA model to account for the patients' treatment field parameters, namely, aperture size, range modulation, air gap, and radiation weighting factor, wR. As a figure of merit for evaluation, we compared our estimated HT values to those calculated by previously-published MC simulations.
Methods
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Patient selection
Because MC simulations had already been performed, the boost treatment fields of the 10-year-old boy of Taddei et al (2009) and the 9-year-old girl of Taddei et al (2010) were selected for this study. In each study, MC calculations were performed using the Monte Carlo N-Particle eXtended code version 2.6b (Pelowitz 2008) to estimate the absorbed dose from external neutrons in each voxel, Dv, of the patients' simulated bodies. They applied the recommendations of the International Commission on Radiological Protection (ICRP) in Publication 92 (2003) to estimate the radiation weighting factor, wR. With these parameters, they determined H in each voxel, v, as:
Each patient's plan included intracranial boost fields. These fields were similar in design to those of treatments for localized brain tumors, such as astrocytomas, ependymomas, and gliomas. Determining and minimizing out-of-field H for pediatric patients with brain tumors such as these is critical because they may have good long-term prognoses and are therefore at risk of developing late-effects of which SMNs are the chief concern (Armstrong et al 2010).
Patient diagnosis, prescription, and treatment planning
In the previous studies, treatment plans for a girl and a boy diagnosed with primitive neuroectodermal tumors were considered. Their treatments included intracranial boosts prescribed to deliver 21.3 Gy in the clinical target volume using PSPT. For the girl, the intracranial boosts comprised three fields of nominal energies (i.e., energies prior to beam shaping) at either 160 MeV or 180 MeV. The boy's two PSPT intracranial boost fields were of slightly lower nominal energies of 140 MeV and 160 MeV. The beam characteristics of the intracranial boost fields for these two children are summarized in Table 1 . Further details of the computed tomography simulations, treatment plans, and MC techniques used for dose calculation can be found in the previous publications.
Translation of the analytical model to a clinical setting
The LSU-MDA analytical model for H considered four different external neutron energy regimes, contained 22 fitting parameters, and was continuous with proton beam energy from 100 to 250 MeV. We adjusted the model for translation to a clinical setting, accounting for wR, spread-out Bragg peak (SOBP), aperture size, and air gap (the LSU-MDA model accounted for distance from the virtual neutron source but not for varying air gaps). We applied correction factors for each of these based on previous publications of generalized, detailed characterizations of the same PSPT treatment unit (Zheng et al 2007b (Zheng et al , 2008 . The equation for our adjusted model was the following: Figure  5a of Zheng et al [2008] ). The wR for the respective proton beam energies of the intracranial boost fields were used to calculate FwR.
An SOBP adjustment factor was created to account for the lack of modulation in the analytical model. FSOBP values were taken directly from Zheng et al (2008) . In these studies, Zheng et al performed MC simulations comparing the neutron ambient dose equivalent per therapeutic proton absorbed dose at isocenter, H*(10)/Diso, from a nominal 250-MeV proton beam of various SOBP widths normalized to a pristine Bragg peak. We used the resulting values in their Figure 9a . The factor reflecting the relative increase in H*(10)/Diso of the medium snout size for the respective SOBP width was directly used for FSOBP (Table 1 ) and applied to each intracranial boost field.
We adjusted the model for the varying size of the aperture in the clinical treatment fields in our study. We derived Fas based on the results of the previous MC studies. Similar to SOBP, Zheng et al performed MC simulations comparing H*(10)/Diso for various aperture sizes and a closed-aperture in their Figure 8 (Zheng et al 2008) . However, this Figure 8 was not normalized to a closed-aperture. Therefore, Fas was determined as the ratio of H*(10)/Diso of the medium snout size of each aperture area to that of the medium snout size with a closed aperture (Table 1) .
To account for air gap, g, Fg was derived from the previous MC studies. Zheng et al (2007) conducted MC simulations to study the effect of distance from the treatment snout on H per the therapeutic absorbed proton dose, Dp, for a 250 MeV proton beam with medium and large snout sizes (their Figure 7) . In our study of pediatric intracranial fields, the air gap was calculated as the difference of the snout position (i.e., distal portion of the treatment unit) and the surface of the patient along the central axis. In order to match this definition of air gap, we calculated air gap from Zheng et al's study as the difference in the snout position and the isocenter minus the upstream radius of the tally volume. Fg was calculated from Zheng et al as the ratio of H/Dp that equated to the air gap of the intracranial fields and H/Dp that equated to the air gap used by Schneider et al to train their model, i.e, 15 cm. Thus, air gaps larger than 15 cm, e.g., those of the girl's fields, would result in Fg values less than 1, and air gaps smaller than 15 cm, e.g., those of the boy's fields, would result in Fg values greater than 1. The air gap of the boy's fields was only 2 cm, which is very rare in clinical applications but was maintained in our study so that we could compare our results with those of the previous publications. Because 2 cm was less than the smallest air gap studied by Zheng et al, we extrapolated beyond the scope of their data using the following logarithmic function:
where HZ/Dp was H/Dp as plotted in their Figure 7 and g was the corresponding air gap (cm). To verify the fitted function, previous MC simulations estimating the neutron equivalent dose of the left posterior oblique (LPO) field of the girl were compared to the similar LPO field of the boy. The main difference between the two fields was the air gap-23 cm for the girl's field and 2 cm for the boy's field. The neutron equivalent dose decreased by a factor of 2.7 when increasing the air gap from 2 cm to 23 cm, Page 4 of 14 AUTHOR SUBMITTED MANUSCRIPT -PMB-107120. R1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t which was consistent with the prediction of the above fitted function. Therefore, the fitted function was used to approximate the numerator of Fg for the boy.
HT/DRx was determined for each component of the adjusted model and for all adjustments. First, we implemented the LSU-MDA model with the adjustment factors using in-house codes and commercial software (version R2014a, MATLAB, The MathWorks, Inc., Natick, Massachusetts) to calculate Hv/DRx. Second, we recycled the same contours for organs and tissues, T, from the previous publications for the girl and boy to compute mass-averaged HT/DRx. We selected out-of-field T associated with site-specific SMN risk, including the esophagus, thyroid, heart, lungs, liver, small bowel, colon, stomach, kidneys, bladder, breast tissue, ovaries, testicles, and prostate. Finally, our values for HT/DRx were compared to those of the previous MC studies of the girl and boy.
Results

Validation of the previous analytical model
The adjustment factors we found to account for SOBP, aperture area, air gap, and wR of each intracranial beam are listed in Table 1 . Only Fg differed considerably between the girl's fields and the boy's fields. Fg, the largest adjustment factor for the boy's fields, increased Hv/DRx by a factor of 2.22 for the boy's fields but decreased Hv/DRx by 36.3% for the girl's fields. The largest adjustment factors for the girl's fields were FSOBP and FwR. Unlike the other adjustment factors, FwR varied for each voxel and therefore, the average FwR was reported. The wR for each field of the MC dataset of the girl and boy are also included in Table 1 . Although the wR approximated from Zheng et al are not explicitly shown in Table 1 , these values of wR were within 3% on average of the previous MC dataset of the girl and boy. Figure 1 shows all HT/DRx values from the girl's fields of the adjusted model compared to those of the previous MC studies. Before we applied any adjustment factors to the model, HT/DRx calculated by the model was less than the MC results for all organs, on average by 57.4% ± 4.8%, i.e., approximately within a factor of 2. After applying all corrections, HT/DRx calculated by the model was less than the MC results for all organs, on average by 20.8% ± 10.0%, with the exception of the bladder for which the model overestimated HT/DRx by 3.0%. The maximum deviation of the model from the MC result was in the breast tissue, for which HT/DRx calculated by the fully adjusted model underestimated the MC result by 39.0%. Figure 2 shows all HT/DRx values from the boy's fields of our adjusted model compared to those of the previous MC studies. Similar to the girl's fields, HT/DRx of the unadjusted model was less than those of the MC for all organs. However, unlike the girl's fields, the unadjusted model grossly underestimated the MC results, on average by 91.4% ± 2.9%. After applying all adjustments, HT/DRx calculated by the model underestimated the MC HT/DRx by less than a factor of 2, at 44.2% ± 17.6% on average for all the organs. Unlike the girl's fields, the analytical model's dose estimation of the boy's fields diverged from the MC results with distance from the field edge. For example, HT/DRx estimated in organs near the treatment field, i.e., esophagus, thyroid, heart, lungs, stomach, liver, and kidneys, were on average 31.7% ± 10.8% lower than the MC result whereas HT/DRx estimated by the model in organs far from the treatment field, i.e., prostate, bladder, colon, rectum, and testicles, were 61.7% ± 5.1% on average lower than the MC result. The model's maximum deviation from the MC result was in the rectum, for which HT/DRx estimated by the model underestimated that of the MC by 65.9%. A c c e p t e d M a n u s c r i p t
Discussion
In this study, we applied an analytical model for estimating equivalent dose from neutrons produced in a PSPT treatment unit and confirmed its ability to reproduce organ doses with accuracy similar to that of MC simulations for two pediatric patients with intracranial tumors. We performed this study independently of the team who developed the model. However, we made adjustments for clinical realism. Specifically, we attuned the model to account for SOBP, aperture area, air gap, and wR.
Our aim was to test the feasibility of using a fast and simple analytical model to estimate external neutron equivalent dose with an acceptable level of accuracy but without the computational overhead and complexity of MC. After adjusting the model for clinical realism, we achieved this with similar accuracy to what was attained when validating MC results against measurements (Fontenot et al 2005 , Wroe et al 2007 , Howell and Burgett 2014 . To estimate organ doses from external neutrons to within a factor of 2 using a simple analytical model is especially noteworthy considering the large uncertainties in wR for neutrons, a radiological protection quantity that attempts to take into account the relative biological effectiveness of neutrons for carcinogenesis ( The impacts of adjusting the model differed between the two test cases. HT/DRx of the unadjusted model adequately estimated the external neutron dose for the girl's fields (by a factor of 2-2.5) but underestimated the external neutron dose for the boy's fields (by a factor of 13). However, after our tested adjustments, HT/DRx estimated by the model was generally within a factor of two of the MC result for both patients. One cause of the underestimation for the boy's was a very small 2-cm air gap between the treatment unit and the patient. A 2-cm air gap is rarely used in proton therapy and it was much smaller than the 15 cm air gap used to train the LSU-MDA model, and our Fg values for this small air gap were extrapolated far beyond the data of Zheng et al. The considerable deviation in the length of the air gap at treatment compared to the training data created an Fg of 2.22 for each of the boy's fields, deviating farther from 1 than Fg of the girl's fields, which were 0.64 ± 0.08 on average.
The HT values after our adjustments to the LSU-MDA model, especially for the girl's fields, were even closer to the HT values of the MC than those of Eley et al for a patient with Hodgkin's Lymphoma (2015). However, they accounted for different factors-range modulation, aperture area, and anatomical heterogeneities-than we did. For example, the application of the model by Eley et al reproduced Hthyroid to within 39% of the MC result while our application of the model estimated Hthyroid to within 13% and 34% of the MC for the girl and boy, respectively. In either case, within or independent of the LSU-MDA team, the model has been demonstrated in clinical cases to estimate HT with accuracy comparable to that of MC or measurements (Agosteo et al 1998 , Polf et al 2005 , Farah et al 2014 and with greatly lessened computational overhead.
Our study had the following limitations. First, we applied the LSU-MDA model to two patients' treatments only. However, the realism of our work is notable. Second, we did not consider other reasonable adjustments to the model. For example, unlike Eley et al, we did not account for water equivalent thickness of heterogeneous tissue nor did we consider their nuclear cross sections.
Page 6 of 14 AUTHOR SUBMITTED MANUSCRIPT -PMB-107120. R1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t Considering actual tissue compositions may affect neutron production by up to 40% (Moffitt et al 2018) . Thus, accounting for tissue heterogeneities is another avenue for a potentially major improvement in the model. Another possible improvement over our adjustments may be to compensate for further complexities, such as the lateral dimensions of the proton beams incident on the aperture, the selfshielding of the aperture block, and integrating over a three-dimensional distribution of secondary neutron generation points in the aperture block rather than assuming a single point source. Although these omissions may have contributed to the general underestimation of HT/DRx values from our adjusted model, we would expect their affects to be minor compared to the adjustments made in this study and in the study by Eley et al. Future developments of a more generalized analytical model may test and, if necessary, account for the effects of these and various other physical aspects of a modern clinical proton beam.
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